| 영문 | infertility, sterility | 한글 | 불임증 |
|---|---|---|---|
| 설명 | 건강한 부부가 일정기간(보통 2년간) 정상적인 결혼생활을 하고 있음에도 임신이 성립되지 않는 상태. 현재 10% 가량의 부부가 붙임상태에 있다고 하는데, 치료의 향상과 더불어 불임률은 저하되고 있다. 불임의 원인은 대별하여 남성측에 요인이 있는 남성불임과, 여성측에 요인이 있는 여성불임이 있다. 남성불임의 원인은 ① 성교장애(성기의 기형-발기부전 등), ② 정자 수송로의 장애, ③ 정자의 형성장애 등이 있다. 여성불임의 원인은 ① 여성 성기의 이상, ② 배란-월경의 장애, ③ 자궁관에 장애가 있어 수정불능인 것, ④ 수정란의 착상 장애, ⑤ 기타 성기의 종양-염증 또는 전신질환의 경우 등이 있다. |
||
| HCG, hCG | Human Chorionic Gonadotropin; 사람융모성성선자극호르몬 1. Placental Glycoprotein Hormone &nbs... |
|---|---|
| ASHI | Association for the Study of Human Infertility |
| BIP | bacterial intravenous protein; biparietal; bismuth iodoform paraffin; Blue Cross interim payment; br... |
| ICU | infant care unit; immunologic contact urticaria; intensive care unit; intermediate care unit |
| OILD | occupational immunologic lung disease |
| male infertility | <radiology> Low sperm count, decreased motility/morphology, autoimmunity (12 Dec 1998) |
|---|---|
| swine infertility and respiratory syndrome virus | A species of arterivirus causing reproductive and respiratory disease in pigs. The european strain is called lelystad virus. Airborne transmission is common. (12 Dec 1998) |
| infertility | <gynaecology> The inability of a couple to achieve a pregnancy or to carry a pregnancy to term after one year of unprotected intercourse. (13 Nov 1997) |
| infertility, female | Inability of a woman to achieve conception. (12 Dec 1998) |
| infertility, male | Inability of the male to effect conception. (12 Dec 1998) |
| female infertility | <radiology> Tubal (30%), partial/complete obstruction, intra/peritubal adhesions, ovulatory (30%), anovulation, luteal phase defect, cervical (less than10%), diminished mucus production, infected mucus, sperm antibodies, pelvic / peritoneal (20%), endometriosis, periadnexal adhesions, TB, uterine (less than10%), abnormal morphology, synechiae, endometritis, myomata, other (less than10%), serum antibodies in female, chronic vaginitis (12 Dec 1998) |
| adjuvants, immunologic | Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (freund's adjuvant, bcg, corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (12 Dec 1998) |
| receptors, immunologic | Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behaviour of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere. (12 Dec 1998) |
| graft enhancement, immunologic | The induction of prolonged survival and growth of allografts of either tumours or normal tissues which would ordinarily be rejected. It may be induced passively by introducing graft-specific antibodies from previously immunised donors, which bind to the graft's surface antigens, masking them from recognition by T-cells; or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity. (12 Dec 1998) |
| monitoring, immunologic | Testing of immune status in the diagnosis and therapy of cancer, immunoproliferative and immunodeficiency disorders, and autoimmune abnormalities. Changes in immune parameters are of special significance before, during and following organ transplantation. Strategies include measurement of tumour antigen and other markers (often by radioimmunoassay), studies of cellular or humoral immunity in cancer aetiology, immunotherapy trials, etc. (12 Dec 1998) |
| contraception, immunologic | Contraceptive methods utilizing immunologic processes. (12 Dec 1998) |
| cytotoxicity, immunologic | The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitised T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. (12 Dec 1998) |
| cytotoxicity tests, immunologic | The demonstration of the cytotoxic effect on a target cell of a lymphocyte, a mediator released by a sensitised lymphocyte, an antibody, or complement. (12 Dec 1998) |
| suppressor factors, immunologic | Proteins, protein complexes, or glycoproteins secreted by suppressor T-cells that inhibit either subsequent T-cells, B-cells, or other immunologic phenomena. Some of these factors have both histocompatibility (I-j) and antigen-specific domains which may be linked by disulfide bridges. They can be elicited by haptens or other antigens and may be mass-produced by hybridomas or monoclones in the laboratory. (12 Dec 1998) |
| desensitization, immunologic | Immunosuppression by the administration of increasing doses of antigen. Though the exact mechanism is not clear, the therapy results in an increase in serum levels of allergen-specific IgG, suppression of specific IgE, and an increase in suppressor T-cell activity. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|